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 ABSTRACT  
Discussion of liver antibody mediated rejection during the 2011, 2013 and 2015 Banff liver sessions 
raised concerns over reliability of complement fragment 4d (C4d) staining, precipitating a global 
survey followed by a tissue microarray staining quality assessment study among centers on formalin-
fixed, paraffin-embedded tissue.  Tissue microarray sections containing tissue plugs of resected 
native and allograft (with acute antibody mediated rejection) liver, heart and kidney (n=33 total 
cores) were sent to 31 centers for C4d staining using local method (s) and pathologist scoring.  
Digital whole slide images (n=40) were then semi-quantitatively scored by 7 experts for background, 
distribution and intensity of portal vein and capillary, hepatic artery, sinusoidal, and central vein 
endothelia and portal and central stromal staining.  Results showed that strong and diffuse portal 
vein and capillary C4d staining, as determined by both local and central pathologists, clearly 
distinguished allografts showing acute antibody mediated rejection from native livers and from 
those with evidence of weaker donor specific antibody.  Downstream vascular endothelial cell C4d 
staining and assessment were more variable and difficult to identify.  C4d staining in the majority of 
laboratories reliably detects acute liver allograft antibody mediated rejection in formalin-fixed, 
paraffin-embedded tissues. Assessment should focus on portal veins and capillaries, sinusoids and 
central veins present in peripheral core needle biopsies. C4d staining in one organ does not always 
translate to staining in another. 
KEYWORDS: Complement fragment 4d, liver allograft, antibody mediated rejection, method, tissue 
microarray 
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1. INTRODUCTION 
Despite Western World abandonment of ABO-incompatible liver transplantation because of acute 
antibody mediated rejection (AMR) in untreated recipients; AMR occurrence in ABO-compatible 
orthotopic liver transplant (OLTx) is still debated because of its low incidence in OLTx [1-7].  
However, accumulating case reports [8-13], cohort studies [14-17] and reviews [7,18], show that 
AMR can cause liver allograft dysfunction and rarely, failure.  Based on published studies and intense 
discussion over a 6-year period AMR has also been incorporated into the Banff scheme for liver 
allograft pathology [19].  
C4d staining is an important, although limited [20], tool used to assist in establishing an AMR 
diagnosis in all solid organ allografts.  Optimal methods of tissue preservation, staining, and 
compartment scoring of C4d deposition have yet to be established for liver allografts, but in general, 
immunofluorescence (IF) on frozen tissue is considered the gold standard.  Unfortunately, most liver 
centers obtain only formalin-fixed paraffin embedded (FFPE) tissues for C4d immunohistochemistry 
(IHC).  Kozlowski et al [16] suggested that IHC antigen retrieval pH is an important determinant of 
C4d staining sensitivity and that staining patterns qualitatively differ between IF and IHC, and only 
the former might be reliable.   
AMR discussions during the last 3 Banff meetings [Paris, France (2011), Comandatuba, Brazil (2013) 
and Vancouver, Canada (2015)] prompted a survey to gauge practices and attitudes as to the 
relevance of AMR in OLTx; C4d usefulness in liver allograft AMR diagnosis; and frozen versus FFPE 
sections.  Based on survey results this TMA reliability was carried out using native and AMR-positive 
kidney, heart plugs, and liver plugs. 
The aims of the study were to: 1. Elicit current views on AMR in OLTx; 2. Determine if C4d staining on 
FFPE sections is able to identify acute AMR in “gold standard” cases; 3. Identify C4d staining 
methods and structures that might be used to standardize an acute liver allograft AMR diagnosis. 
2. MATERIALS AND METHODS 
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2.1. Surveys  
Two internet surveys were initially conducted (see supplementary material for details), both in 2013: 
The first focused on current understanding and attitudes of hepatologists, surgeons, immunologists 
and pathologists toward liver allograft AMR; the second queried centers regarding C4d staining 
methods, reliability and interpretation for liver allografts on FFPE sections.  Banff-participating and 
other larger international OLTx centers were targeted as key opinion leaders, but participants were 
encouraged to disseminate the survey. 
2.2. Tissue microarray production  
Failed allografts are required to obtain enough tissue to create a TMA for multicentre analysis; 
diagnostic biopsies, after clinical assessment do not provide enough tissue. Unfortunately, liver 
allografts that failed from AMR are sparse, often historical, lacking complete solid phase HLA DSA 
testing and having no matched fresh frozen tissue for comparison to “gold standard” IF. A 33-plug 
tissue microarray (TMA) using FFPE tissues was developed and included peri-hilar and peripheral 
plugs of 5 liver allografts from sensitized recipients which failed within 1-month post-transplant, 
with a strong suspicion of acute AMR as the cause of graft failure. Details of the OLTx histological, 
immunology and clinical features are shown in Table 1. As controls, the TMAs included 5 non-
transplant (native) hearts, 5 native kidneys, 5 native livers (with a peri-hilar and peripheral plug from 
each), 2 cardiac AMR cases and 6 kidney AMR cases.  Native organs with an immunological disease 
process and allografts without AMR were avoided because: a) simultaneous donor specific antibody 
(DSA) was felt to be necessary; and b) a complement deposition role in other diseases has not been 
thoroughly investigated, especially for livers.  Two kidney AMR cases were excluded because of 
extensive necrosis of the plug, which made comparisons unreliable.  Chronic AMR was not 
considered.   
2.3. Tissue microarray staining and scoring  
Sixty-eight TMA unstained sections were mailed to 31 centers: 2 sections were sent to 25 centers 
and 3 sections to 6 centres that used 2 methods for C4d staining.   TMAs were then stained using 
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local C4d method(-s), scored locally using a centrally-devised scoring template with instructions, 
between 33 and 38 local scores were received for each plug. Slides were returned to the University 
of Pittsburgh Medical Center for creation of digital whole slide images (WSI).  Forty stained slides 
from 31 centers (13 North America, 13 Europe, 2 Japan, 2 Australia and 1 South America) were 
assigned an anonymous TMA number and converted to WSI. 
All WSIs were semi-quantitatively scored by 7 central pathologists blinded to any meta-data. Each 
TMA plug was assessed for background staining (0 no background, 1 some background that does 
not; or 2 high background that does, interfere with interpretation).  Heart interstitial capillaries and 
kidney peritubular and glomerular capillaries were graded from 0-3 based on a combination of 
distribution and intensity: 0 no staining, 1 equivocal staining, 2 weak focal staining and 3 
moderate/strong diffuse staining.   
Eight separate liver compartments were scored separately for distribution and intensity:  portal vein 
(PV), portal capillary (PC), hepatic artery (HA), sinusoids (SIN) and central vein (CV) endothelium, and 
portal and central/perivenular stroma. Distribution was scored as 0: no staining; 1: <10%; 2: 10-50%; 
and 3: >50% structures stain positively.  Intensity was scored as: 0 no staining; 1: weak; 2: moderate; 
and 3: strong staining.  
Local pathologists (25 at 1 center, 5 at 2 and 2 at 3), also blinded to meta-data, scored 32 TMAs 
using glass slides.  Median values were used for >1 local pathologist. Hepatocyte cytoplasmic 
staining was ignored.   
2.4. Collection of methodology used 
Each center provided detailed C4d staining methodology including fixative, manual or automated 
(company) staining method; method of antigen retrieval (heat or enzyme); antigen retrieval pH; 
endogenous peroxidase blocking; wash buffer; and primary and secondary sources (suppliers and 
catalogue numbers) and concentrations.  
2.5. Determining compartmental specificity of C4d in acute liver allograft AMR?   
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Staining distribution and intensity were compared between peripheral and peri-hilar plugs to 
determine if staining intensity decreased peripherally via absorption.  
2.6. Selection of the “best” TMA staining method  
The peripheral plugs of OLTx 1 and 2, which had the strongest and most diffuse staining by the 
majority of centers (figure 1) were used in the first step. For each compartment (PV, PC, HA, SIN and 
CV) the methods that showed strong and diffuse staining with no background were identified.  Of 
these, only the subset that adequately stained all compartments were determined.  Methods that 
also showed staining of structures in OLTx 3, 4 or 5 with weak background without interference with 
interpretation were added. These “best” methods showed the most sensitive and specific staining. 
2.7. Do the methods that stain liver also work on kidney and heart?   
Median scores for each positive AMR plug was then assessed for each TMAs identified as “best” by 
assessment of the liver plugs. 
2.8. Statistical analysis  
Statistical analysis was performed using SPSS version 22 (IBM analytics).  A Kruskal-Wallis test was 
used to assess distribution or intensity differences between any OLTx plugs or native liver plugs for 
each TMA.  A Mann-Whitney tests was used to assess differences between native and Tx plugs. 
Wilcoxon Rank sum test assessed difference between the peri-hilar and peripheral plugs. Within 
peripheral plugs a Friedman test assayed for differences in both distribution and intensity of staining 
throughout the vascular tree.  Statistical analysis of kappa values was performed using STATA v10, 
StataCorp. 2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP, on the best 
stained TMA (30) and best liver Tx plug (OLTx1), between central reviewers.  
3. RESULTS: 
3.1. General internet AMR survey (Survey 1)  
Fifty-six participants (35 pathologists, 12 hepatologists, 7 surgeons and 2 immunologists) from 41 
centers (performing a median range of 76-100 OLTx/year from a minimum <25 to a maximum >175) 
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in at least 13 countries (17 North America, 17 Europe, 2 Australia, 1 Japan, 1 South America and 3 
unstated country) responded to survey #1.    
Ninety-one percent of responders (51/56) considered evidence supporting occurrence of liver 
allograft AMR at least moderately convincing, but only 46% thought AMR was definitely a cause of 
graft injury.  Forty-nine percent (20/41) routinely performed some testing for anti-donor antibodies 
pre-transplant: 4/41 (10%) directly tested for HLA DSA while 10/41 (24%) used crossmatch testing to 
monitor anti-donor reactivity and 6/41 (15%) used both methods. Fifteen (15/41; 36%) centers did 
no testing. No center prophylactically treats recipients based on preformed DSA results regardless of 
testing methods.  However, in up to 50%, DSA results influence management when there is no other 
cause of graft dysfunction and other evidence of AMR. Post-Tx protocol DSA testing is uncommon 
(7% by protocol and 10% commonly if unexplained graft dysfunction) with about half the centers 
only rarely testing for DSA in the event of unexplained graft dysfunction. Despite this most centers 
(76%) have made an acute AMR diagnosis and 75% believe current acute liver allograft AMR criteria 
are adequate: suspicious histology; positive C4d; appropriate clinical setting; proven DSA; and 
exclusion of other possible causes.   
The majority 38/41 (93%) of centers conduct liver allograft biopsy C4d staining, at least occasionally, 
mostly 20/38 (53%) to further investigate otherwise unexplained graft dysfunction; 11/38 (29%) 
perform on all cases where the histology is suspicious and 6/38 (16%) perform routinely. Most 
centers 30/41 (73%) perform C4d on FFPE sections only.   
3.2. Pathologist survey (Survey 2)  
15 pathologists representing 12 centers (median number transplants: 76-100) undertook survey 2 
and 6 other pathologists from different centers provided some extra relevant information in the first 
survey included here (North America (n:8); Europe (n:7); Japan (n:1); Australia (n:1). One 
pathologist/center used only C4d IF and was excluded.  
Participating laboratories had experience with C4d immunostaining in other, non-liver, allografts: 
11/13 (85%) also stained kidney, 9/13 (69%) heart, 5/13 (38%) lung, 5/13 (38%) pancreas and 1/13 
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(8%) intestine Tx biopsies.  Most 9 (69%) labs used the same C4d staining method in livers as other 
organs, but 2 used IF on kidney and heart. Most centers (35/37, 95%) used FFPE sections for liver 
C4d staining, but 5 also used frozen section, and 2 use only frozen sections.  Five centers did not 
answer or did not know.  Nine of 15 (60%) pathologists assess at least 1 other organ.  
Pathologists were uncertain about expected C4d staining patterns during acute AMR: 9/14 (64%) 
considered PC, 8/14 (57%) PV, 2/14 (14%) PS, 3/14 (21%) HA, 7/14 (50%) SIN, 3/14 (21%) CV positive 
in acute AMR. Nobody considered hepatocyte cytoplasmic staining to be an acute AMR feature, as 
this occurs in any necrotic cell as a result of opsonisation of dead/dying cells by CRP with activation 
of complement [21,22, 23] (Figure 2). Despite a majority of centers employing C4d immunostaining 
only one of fourteen (7%) pathologists was satisfied with the results; 7 (50%) were dissatisfied with 
sensitivity compared to other organs and/or compared to histological suspicion. The majority 10 
(71%) felt uneasy evaluating the C4d stain because of a lack of correlative DSA data and/or 
infrequency of use. 
3.3. TMA results 
3.3.1. Background staining  
The vast majority (39/40) TMAs, had weak or no background that did not interfere with 
interpretation. 
3.3.2. Native control liver plugs   
No staining of any structures in any TMA method was seen in peripheral native plugs yielding a 
median score of ”0”.  Occasional “false positives” were detected in peri-hilar native plugs: 1) weak 
focal PV staining in one TMA with high background; 2) weak focal PC staining in multiple TMAs, as 
assessed by two central scorers; 3) HA staining in three native livers in many TMAs; 4) weak portal 
stromal staining in four native plugs in many TMAs.  Sinusoids, CVs and central stroma were 
occasionally missing from peri-hilar plugs, but when present were negative. 
3.3.3. Peri-hilar versus peripheral staining and native versus transplant staining 
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There was significantly more diffuse and intense staining of OLTx than native liver plugs for all 
structures in peripheral and peri-hilar plugs, except for portal and central stroma in the latter.   
Peri-hilar and peripheral Tx plug staining for each structure was similar: there was significant, but 
minimally (same median values), more diffuse and intense staining of peri-hilar plugs than peripheral 
plugs for PV (median score 1), PC (median score 1), HA (median score 0) and portal stromal (median 
score 0) staining for both distribution and intensity (p<0.001 for all).   
3.3.4. Peripheral plugs 
Within peripheral plugs, staining detected diminishes along the flow of blood (p<0.001) with the 
greatest staining in portal vascular structures (PV, PC and HA) compared to more peripheral vascular 
structures (sinusoids and CVs).  OLTx plug staining varied in intensities and distributions (Figure 1A), 
as expected.  OLTx1 and OLTx2 showed the strongest and most diffuse staining, particularly of PVs, 
PC and HA endothelium (not elastic lamina; Figure 3). Staining variability existed among different 
methods (Figure 1B): some methods working well and others not working, at all, even on plugs that 
stained strongest at other centers. 
All 40 TMAs showed diffuse (100%) and 38/40 (95%) strong (grade 3) PV staining in OLTx1 (Figure 
4a); the remaining 2 showing moderate intensity staining. Most (84%) showed diffuse and at least 
moderate 31/40 (77.5%) C4d staining of OLTx2, with 15/40 (37.5%) strong. Two TMAs failed to 
detect C4d staining in OLTx2, 1 showed weak/suboptimal staining for both intensity and distribution 
and 5 showed weak, but at least moderately diffuse, staining and one plug had fallen off the slide. 
Two TMAs showed staining of PVs in OLTx 4, with no staining detected by any TMA for OLTx 3 or 5, 
however, half of the OLTx3 plugs had fallen off the slide.  Median central pathologist PV scores were 
similar with a kappa value of 0.78 (good) for distribution and 1 (very good) for intensity.  
PC showed diffuse and strong staining (Figure 4b) in 38 of 40 (95%) TMAs with the remaining 2 
showing diffuse moderate staining on OLTx1. For OLTx2 1 plug had fallen off, 37 of 39 (94.9%) TMAs 
showed diffuse (>50%) staining of OLTx2, 2/39 moderately diffuse (10-50%) and 1 focal (<10%) 
staining, with 35/39 (89.7%) showing at least moderate staining.  One TMA showed suboptimal 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
11 
 
staining and 2 weak staining of OLTx2. Two (5%) TMAs show weak and focal staining of OLTx5, but 
also had weak background staining. There was no staining of OLTx3 or 4.  
Individual central pathologist PC scores showed a kappa value of 0.62 (good) for distribution and 
0.81 (very good) for intensity.  
HA endothelium staining was at least moderately diffuse (10-50%) and moderately intense by all 
methods in OLTx1 compared with 32/39 (82%) at least moderately diffuse and intense in OLTx2.  
One method did not stain OLTx2, 6 were suboptimal and 1 plug had fallen off.  Two methods stained 
HAs in OLTx3 and 1 in OLTx5, none showed any staining of OLTx4.  Two central pathologists 
“underscored” the HA compartment compared to the other 5 with kappa values of 0.39 (fair) for 
both distribution and intensity. 
No portal stromal staining was detected by any method of OLTx1 or 4, however, 7 methods showed 
generally weak and focal portal stromal staining in OLTx2, 2 of OLTx3 and 1 of OLTx5.   
Sinusoidal staining was detected in OLTx1 and OLTx2 (Figure 5 and 6), but was weaker and less 
diffuse compared to portal structures (Figure 1). Seven TMAs showed sinusoidal staining in both 
OLTx1 and 2 and 13 more showed sinusoidal staining in either OLTx1 or 2.  Central pathologists 
tended to cluster into 2 groups (Figure 6):  3 detected sinusoidal staining and 4 did not. Therefore, 
kappa agreement values were 0.29 (fair) and 0.3 (fair) for distribution and intensity respectively.  
Reassessing the data using only the 3 central pathologists who identified sinusoidal staining showed 
that all TMAs displayed sinusoidal staining in OLTx1 and 2 with a median of 1 (<10%) for distribution 
and median of 2 (moderate) for intensity of staining.  Although 56% of OLTx3 sections could not be 
assessed, sinusoidal staining was detected in 24.5% of the remaining plugs. Two TMAs (8 &14) were 
the strongest: median of 2 for distribution and 1 and 2 for intensity, respectively. Of note PV and PC 
staining was not detected in OLTx3 (Figure 4).  
CV endothelial staining (Figure 3) was seen in 7 TMAs in OLTx1: median distribution (focal <10%) and 
intensity (weak).  No CV staining was detected in the other 4 Tx plugs.  Central pathologist CV scoring 
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variability showed a kappa value of 0.44 (moderate agreement) for distribution and 0.63 (good 
agreement) for intensity.  No central stromal staining was detected by any method or any scorer. 
Hepatocyte cytoplasmic staining was not graded due to a unanimous agreement that cytoplasmic 
staining was a non-specific feature of necrosis, but hepatocyte surface membranous C4d was seen in 
some AMR livers (Figure 7). 
3.3.5. Comparison of local and central scores  
Central and local pathologist (median scores) generally agreed (Table 2).  When variances occurred, 
local pathologist scores drifted higher, especially for sinusoidal scoring: 25.3% higher, 2.5% lower 
compared to central pathologist medians.  Of the total of 1920 different scores for the 5 peripheral 
liver plugs for PV, PC, HA, SIN and CV for the 32 TMAs: local scores were higher in 271 (14.2%) and 
lower in 79 (4.1%).  HA showed similar rates of increased and decreased scores (11.9% v 10.9%).  
 
3.3.6. Best methods and performance in kidney and heart 
Six methods (TMAs 10, 16, 20, 30, 37 and 39) showed the strongest and most diffuse staining 
combined with the cleanest background of OLTX1 and 2 and with staining of structures within other 
liver Tx plugs (Figure 8 and Table 3).  Results showed equal numbers of high and low pH of antigen 
retrieval; Cell Marque is the most common primary antibody.  Of the two deemed “best” based on 
the strongest staining of more structures (TMA10 and TMA 30) TMA 10 is fully automated whilst 
TMA 30 included a manual antigen retrieval step, which is not ideal for a clinical lab.  
Conceding difficulties with sinusoidal staining and interpretation, median scores were reassessed 
using only 3 pathologists detecting sinusoidal staining.  Three, TMAs 8, 14 and 39 (also included in 
the above list), were best for sinusoidal staining and TMA 37 shows broader staining of PV and PC.   
C4d staining correctly identified the AMR-positive heart controls (median of 3 for both intensity and 
distribution) with minimal background staining.  The four “best” liver methods (TMA 14, 16, 20 and 
37) did not perform optimally on the heart with false negative staining of positive controls, the 
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remainder (TMA 8, 10, 30, 39) worked well with strong diffuse staining of positive controls. TMA 30 
was the cleanest with no equivocal staining of the native plugs.  
Only 6 methods showed weak focal or moderate diffuse staining of PTCs (TMA 8, 10, 14, 17, 24, 25) 
and 3 (TMA 10, 14 16) weak focal or moderate diffuse of glomerular capillaries, with 2 showing 
moderate/strong staining of both (TMA 10, 14).  Both of these worked well on liver. The remaining 6 
“best” liver methods are suboptimal for kidney with false negatives. 
Overall, TMA 10 (Table 3) produced the “best” results for detecting AMR in kidney, liver, and heart 
allografts.   
4. DISCUSSION 
This study accomplished its intended goals, it:  1) elicited views on acute liver allograft AMR with the 
majority of centers agreeing that acute AMR has the potential to damage liver allografts; 2) showed 
FFPE C4d IHC is able to detect specific staining for acute liver allograft AMR in gold standard cases; 3) 
identified C4d staining methods and structures that can be used to standardize the diagnosis. In 
addition, for many pathologists involved this was the first unequivocal liver allograft C4d staining 
they had seen. It also identified several centers in need of C4d staining method improvements. 
Uncertainty about a diagnosis of acute AMR [24] is likely attributable to a combination of factors 
including rarity of occurrence, inattention to portal microvascular changes, and lack of C4d staining 
and DSAs testing on a regular basis.  However, indication C4d staining is substantially more 
widespread than post-Tx DSA testing (93% versus 61%) to investigate otherwise unexplained graft 
dysfunction.    Protocol C4d staining of all biopsies (16%) is also more widespread than protocol DSA 
testing (7%), both well-short of kidney and heart Tx practices [20].   
IF on frozen tissue is the gold standard for staining because antigens are not altered by fixation 
rendering the approach more sensitive than IP on FFPE liver sections [14,15].  We identified that 
most (79%) liver centers do not routinely collect a second biopsy fragment for freezing, and FFPE 
sections are also used for C4d staining in other organs at the majority of centers. Whilst 3 – 4 mm of 
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tissue could be diverted to IF studies from needle cores > 2.0 cm length without compromising H&E 
diagnosis, this necessitates the tissue arriving unfixed which may not always happen, thus a method 
that works on FFPE is desirable. 
This study showed that IP on FFPE is able to detect gold standard acute AMR cases, however, less 
florid cases might be missed. The staining pattern can be different between IF and IP with the latter 
showing predominantly portal microvascular endothelial staining and less sensitive sinusoidal 
staining [15].  In addition, intensely positive C4d staining might be more difficult to detect in “old” 
cases stored in paraffin blocks for > 10 years, particularly with the current use of automated 
platforms as OLTx cases 3-5 were historically C4d positive. Portal stromal C4d staining, a feature of 
severe AMR in ABO-incompatible OLTx [25], is often present in AMR in ABO compatible OLTx, as 
previously suggested [26,27], perhaps related to usually more severe damage seen in ABO-I grafts.  
Most acute liver AMR cases with strong and diffuse PV and PC staining also showed weak patchy 
sinusoidal C4d staining.  One case, however, showed a sinusoidal-predominant staining pattern, 
similar to that described by Bellamy [27].  Perhaps a different antigenic target (non-HLA DSA) is 
responsible for the sinusoidal staining.  Sinusoidal staining also seems more difficult for pathologists 
to recognize as evidenced by the lower kappa values, compared to the PV and PC staining.  However, 
it should still be assessed, routinely, along with all other endothelial and stromal cells 
compartments.  Hepatocyte membranous staining detected in some liver AMR plugs might 
represent anti-class I DSA or non-HLA DSA. 
Strong and diffuse smaller portal tract PV and PC endothelial C4d staining in peripheral core needle 
biopsies, recognized equally-well by local and central pathologists, clearly distinguished acute liver 
allograft AMR plugs from native livers.  Staining in larger portal tracts should be interpreted with 
caution as occasional “false” positives were seen in most structures in peri-hilar native plugs.  
Decreased staining intensity from the proximal to distal liver circulation suggests that the large liver 
mass endothelial surface absorbs circulating antibody and staining becomes weaker distally, 
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consistent with increased risk for acute AMR in reduced-sized grafts [28].  The abrupt transition 
between PV and PC C4d positivity and weak sinusoidal may relate to absorption of immune 
complexes and antibody via Fc receptors by both Kupffer and liver sinusoidal endothelial cells [29] 
which may contribute to liver allograft AMR resistance and protection of simultaneous kidneys and 
heart allografts from the same donor [30,31].  HA C4d staining might be weaker than the PV and PC 
because of higher pressures and faster arterial flows [32] that interfere with DSA-antigen binding. 
Only one C4d staining method, TMA 10, worked well on all organs tested, suggesting that most 
multi-organ centers should modify their technique. Antigen retrieval pH was found to be dependent 
on the local approach with both high and low pH acceptable in different protocols and no single 
primary anti-C4d antibody source stood out.  Only a few centers were alerted to the need to 
improve their local C4d staining method.   
A study weakness is that primarily only “gold standard” acute OLTx AMR cases, all obtained from 
liver allografts that failed within 1 month, were included.  However, this purposeful design ensured a 
majority of major centers would be able to detect such cases.  C4d staining of the AMR cases lacked 
apparent sensitivity suggesting that false positive staining requiring a native control with an 
immunological disease process and liver allografts that have failed from non-AMR rejection 
(something difficult to prove with the historic lack of DSA data) was not an issue.  Following 
optimisation of staining techniques further studies of other immunological processes occurring 
within liver allografts eg recurrent or de novo viral hepatitis and recurrent autoimmune diseases are 
warranted to rule out any potential source of positive staining which would result in false positive 
staining for AMR.  Chronic AMR with waxing and waning DSA and C4d staining needs further study 
including histological criteria refinement [33]. 
5. CONCLUSIONS   
The concept of acute liver allografts AMR is widely accepted and C4d IHC staining of FFPE liver 
biopsies appears to be a suitable substitute for detecting gold standard cases.  Small portal tract PV 
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and PC endothelial cell C4d staining are the most sensitive and reliable target structures, and 
sinusoidal staining can occur in isolation. Further multicentre TMA studies based on failed allografts 
with contemporaneously proven DSAs, using current solid phase assays, with ideally both fresh 
frozen and FFPE tissue to be able to compare IF and IP would be useful to confirm and refine these 
findings, however such samples are sparse. 
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FIGURE AND TABLE LEGENDS 
Figure 1: Comparison of Native and Transplant C4d staining and the influence of method used 
A. Median central pathologist Complement fragment 4d (C4d) intensity (int) and distribution (dist) 
staining scores for all liver plugs for all methods.  OLTx 1 and 2 plugs had stronger and more diffuse 
staining portal microvascular endothelial cell staining. No staining was detectable in peripheral 
native livers. B. Staining differences among methods (centers) on different liver structures: some 
methods (centers) were suboptimal or failed to work in comparison to others. Colour codes for each 
of the 40 tissue micro arrays (TMAs) (sites/centers) shown below the graph. 
Figure 2:  Ischemic coagulative necrosis.  
C4d immunostained section showing geographic areas of ischemic coagulative necrosis staining with 
C4d.  The staining in necrotic hepatocytes is cytoplasmic. 
Figure 3:  Portal and Central C4d staining.   
Liver transplant plug showing strong and diffuse Complement fragment 4d (C4d) staining of portal 
vein and capillary staining within a portal tract (PT) and weaker staining of central vein (CV) 
endothelial cells.    
Figure 4: Median scores of central scorers for portal veins and capillaries. 
Central scorer median for A. Portal vein (PV); and B. Portal capillaries (PC) staining in each liver 
transplant plug by each method.  Transplant (Tx) 1 and Tx2 show diffuse and strong PV staining by 
all, but two, methods whilst staining is not detected in Tx3 and 4 and only 2 methods detect staining 
in Tx5.   Tx1 and 2 show PC staining by most methods whilst staining is not detected in Tx3 and 4 and 
only 2 methods detect staining in Tx5.  Colour codes for each of the 40 tissue microarrays (TMAs) 
shown below the graft. Distribution (dist) and intensity (int). 
Figure 5. Sinusoidal C4d staining  
There is linear staining of sinusoidal endothelium of a liver transplant plug with patchy 
intrasinusoidal serum staining.   
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Figure 6:  Median scores of central scorers for sinusoids 
A. Central scorer medians for sinusoidal staining for each liver transplant plug by each method.  
Many methods fail to detect sinusoidal staining in Transplant (Tx)1 and 2. Colour codes for each of 
the 40 tissue microarrays (TMAs) shown below the graft. Distribution (dist). Intensity (int) B. Median 
scores for distribution and intensity of sinusoidal staining for each central scorer for each liver plug.  
Three central scorers detected sinusoidal Complement fragment 4d (C4d).  
Figure 7. Hepatocyte C4d staining 
Membranous hepatocyte staining (red arrows) was seen in some liver transplant plugs with negative 
hepatocytes also seen (green arrows). Focal sinusoidal (blue arrow) is also seen.  Strong staining of 
portal capillaries is seen within a portal tract (PT). 
Figure 8:  Best methods 
Graphs showing the central scorer medians for the 6 best methods as judged by central scorers. 
These methods showed the strongest and cleanest staining of the majority of compartments, 
predominantly of Transplant (Tx)1 and Tx2.  Distribution (dist). Intensity (int). 
Table 1: Immunological details of the failed liver allograft plugs, further clinical details and 
histological features supportive of AMR (antibody mediated rejection).  Microvasculitis (portal or 
sinusoidal) refers to the accumulation of inflammatory cells within the vessel with or without 
swelling of the endothelial cells. C4d Complement fragment 4d; DSA donor specific antibody; MHC 
major histocompatibility complex; HAT hepatic artery thrombosis; AHG anti-human globulin; DTT 
diethiothreitol. *Modified AMOS method involves the addition of washing steps after the initial 
incubation of donor cells with the patient serum prior to the addition of complement described in 
Transplantation 1969; 7(3): 220–223. 
Table 2: The number and percent of local reads for both intensity or distribution for each structure 
that are either increased (↑) or decreased (↓) compared to the median score of the central 
pathologists for the 32 TMAs where at least one local pathologists scored the TMA.  There are a total 
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of 320 reads for each structure (32 TMAs with 5 peripheral plugs and 2 reads / plug (distribution and 
intensity).  The local pathologists tended towards the higher end of the central pathologists range of 
scores. PV portal vein; PC portal capillary; HA hepatic artery; SIN sinusoid; CV central vein. 
Table 3: 8 methods were identified as the best out of the 40 TMAs for staining of acute AMR in liver 
allografts, of these only TMA 10 works well on liver, kidney and heart. 
Manufacturer details: Ventana Medical Systems Inc. A member of the Roche Group, Basel, 
Switzerland; Leica Biosystems, Buffalo Grove, Illinois; Dako, Santa Clara, California; Cell Marque, 
Rocklin, California; DB Biotech, Kosice, Slovakia; AbD Serotech part of Bio Rad Laboratories Inc, 
Hercules, California; ALPCO, Salem, New Hampshire; Biomedica Medizinprodukte, Vienna, Austria 
SUPPORTING INFORMATION 
1. Survey 1:  The questions asked in the first survey to gauge current understanding and 
attitudes of hepatologists, surgeons, immunologists and pathologists toward liver allograft 
AMR. 
2. Survey 2:  The questions asked in the 2nd survey to pathologists utilising formalin fixed 
paraffin embedded sections for C4d staining about method, assessment and reliablility of 
staining. 
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TABLE 1.  IMMUNOLOGICAL AND CLINICAL DETAILS OF LIVER TRANSPLANT PLUGS 
 
OLTx number Day post-Tx 
failed 
Antibody detection method Further comment Histological features 
supportive of AMR 
1 17  Pre-solid phase era.  99% panel reactive 
antibody, complement dependent 
cytotoxicity +ve, B cell flow crossmatch 
+ve 
Combined liver/kidney 
transplant. Kidney is KTx1. 
Both organs failed from AMR 
Portal microvasculitis with a 
ductular reaction.  Sinusoidal 
microvasculitis. 
2 18 DSA +ve for MHC class I and II. Sum 
mean fluorescence intensity 18000 
HAT present Portal microvasculitis, inlet 
venulitis and portal oedema. 
3 23 Pre-solid phase era. Strong +ve B cell 
crossmatch using modified AMOS 
method* before transplantation 
AMR felt to be at least 
partially responsible at the 
time of allograft failure with  
Portal microvasculitis with a 
ductular reaction. C4d 
positive staining at the time 
(2000) 
4 24 Pre-solid phase era. Negative T and B 
cell crossmatch using modified AMOS 
method* at the time of transplantation, 
but B cell crossmatch became strongly 
positive several days before allograft 
failure 
HAT present, AMR felt to be 
at least partially responsible; 
(2003)  
lymphocytic arteritis, portal 
microvasculitis, focal 
ductular reaction, sinusoidal 
microvasculitis.   
5 30 Pre-solid phase era. Strong positive T 
cell crossmatch using AHG and DTT 
before transplantation 
AMR felt to be at least 
partially responsible at the 
time of allograft failure  
Arteritis, portal 
microvasculitis with a 
prominent ductular reaction, 
portal oedema, prominent 
sinusoidal microvasculitis. 
C4d positive staining at the 
time (2003) 
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TABLE 2. 
LOCAL VERSUS CENTRAL MEDIAN SCORES FOR PERIPHERAL LIVER TRANSPLANT PLUGS 
 
 PV PC HA SIN CV 
 ↑ ↓ ↑ ↓ ↑ ↓ ↑ ↓ ↑ ↓ 
NUMBER 63 11 42 14 38 35 81 8 47 17 
PERCENT 19.7% 3.4% 13.1% 4.4% 11.9% 10.9% 25.3% 2.5% 14.7% 4% 
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TABLE 3.   
DETAILS OF THE “BEST” METHODS FOR C4D STAINING IN LIVER ANTIBODY MEDIATED REJECTION 
 
TMA Manual 
step 
pH 
antigen 
retrieval 
Platform 1o Antibody Company Concentration Detection 
8 No high Ventana 
Benchmark 
Ultra 
Polyclonal 
(rabbit) 
Cell 
Marque 
Prediluted Ultraview 
10 No high Leica Bond III Cocktail 
monoclonal 
(SP91) + 
polyclonal 
(rabbit) 
Cell 
Marque 
Both 1:50 Bond 
polymer 
refine 
12 No High Dako PT link Clonal 
(rabbit) 
DB Biotech 1:4000 Envision 
14 No Low Ventana XT Clonal 
(rabbit) 
DB biotech 1:100 Ultraview 
16 No Low Leica 
BondMax 
ER1 
Clonal 
(rabbit) 
DB Biotech 1:100 Bond 
polymer 
refine 
30 Yes 
(waterbath 
antigen 
retrieval 
Low Dako PT link Monoclonal 
(SP91) 
Cell 
Marque 
Neat Envision 
37 No Low Ventana XT 
Benchmark 
Polyclonal 
(rabbit) 
AbD 
serotec 
1:15 Ultraview 
39 No High Ventana Polyclonal 
(rabbit) 
ALPCO/ 
Biomedica 
1:50 Ultraview 
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HIGHLIGHTS 
 
 C4d detects liver antibody mediated rejection in formalin fixed sections 
 C4d predominantly stains portal veins and capillaries in formalin fixed tissues 
 C4d methods do not work equally across all transplanted organs 
 The most sensitive C4d staining methods which work across all organs are provided 
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Sinusoidal C4d Staining
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